Patients diagnosed with acute diarrhea associated with C. difficile infection (mild to moderate) require effective treatment. Clinical cure
Conditions
Interventions
Two 250 mg of S. boulardii CNCM I-745 capsules were administered every 12 hours orally for 10 days, and 125 mg of vancomycin was taken orally every 6 hours for 10 days.,Two capsules of placebo were ad
Experimental Drug,Placebo Comparator Drug
S. boulardii, a non-pathogenic yeast,Placebo
Sponsors
Chiang Mai University
Eligibility
Sex/Gender
All
Age
20 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients were 20 years or older 2. Diagnosis of mild to moderate C. difficile infection, defined by the presence of nosocomial diarrhea (more than three unformed bowel movements in 24 hours) and detection of C. difficile, either toxin A or B, in a stool sample obtained within 48 hours before randomization.
Exclusion criteria
Exclusion criteria: 1. Severe C. difficile infection 2. Prior history of C. difficile infection 3. Presence of other known causes of diarrhea 4. History of chronic intestinal disease 5. History of abdominal surgery within the past three months 6. Severely immunocompromised state 7. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cure 56 days Rate of clinical cure | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrent Clostridium difficile infection 56 days Rate of recurrent infection,Global cure 56 days Rate of global cure,Diarrhea outcomes 56 days Duration of diarrhea, Total diarrheal day, Rate of diarrhea | — |
Countries
Thailand
Contacts
Public ContactFaculty of Medicine Chinag Mai University
Chiang Mai University
Outcome results
None listed